{"id":"anticholinergic-deprescription","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2105187","moleculeType":"Small molecule","molecularWeight":"405.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is not a drug itself, but rather a deprescribing strategy that involves the gradual withdrawal of anticholinergic agents (medications that block acetylcholine receptors) from patients' regimens. Anticholinergics are associated with increased risk of cognitive impairment, falls, and other adverse effects, particularly in older adults. Deprescription aims to improve patient outcomes by eliminating unnecessary anticholinergic burden while managing underlying conditions through alternative therapies.","oneSentence":"Anticholinergic deprescription is a clinical practice of systematically reducing or discontinuing anticholinergic medications to minimize cognitive and physical adverse effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:27:26.437Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of anticholinergic medication burden in patients taking multiple anticholinergic agents"},{"name":"Prevention of cognitive decline and delirium in older adults"},{"name":"Reduction of fall risk in elderly patients"}]},"trialDetails":[{"nctId":"NCT06562608","phase":"PHASE4","title":"Anticholinergic Deprescription in Schizophrenia","status":"RECRUITING","sponsor":"Deepak K. Sarpal, M.D.","startDate":"2025-02-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":105},{"nctId":"NCT07043803","phase":"NA","title":"Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2025-07-16","conditions":"Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder","enrollment":111},{"nctId":"NCT04612166","phase":"NA","title":"Medication Empowerment and Deprescription for Safety (MEDS) Study","status":"UNKNOWN","sponsor":"University of Iowa","startDate":"2020-08-01","conditions":"Aging, Fall Injury","enrollment":398}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anticholinergic Deprescription","genericName":"Anticholinergic Deprescription","companyName":"Deepak K. Sarpal, M.D.","companyId":"deepak-k-sarpal-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anticholinergic deprescription is a clinical practice of systematically reducing or discontinuing anticholinergic medications to minimize cognitive and physical adverse effects. Used for Reduction of anticholinergic medication burden in patients taking multiple anticholinergic agents, Prevention of cognitive decline and delirium in older adults, Reduction of fall risk in elderly patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}